Log in

Relevant bibliographies by topics / Prostate cancer immunotherapy / Journal articles

To see the other types of publications on this topic, follow the link: Prostate cancer immunotherapy.

Journal articles on the topic 'Prostate cancer immunotherapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Prostate cancer immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Fay, Emily K., and Julie N. Graff. "Immunotherapy in Prostate Cancer." Cancers 12, no. 7 (2020): 1752. http://dx.doi.org/10.3390/cancers12071752.

Full text

Abstract:

Immunotherapy encompasses a wide range of therapies to engage the immune system to target malignancies. In recent years, immunotherapy has made a major impact on treatment of metastatic cancer and has altered standard of care for many tumor types. However, predicting and understanding responses across tumor types has been challenging. While some metastatic cancers have shown dramatic responses to immunotherapy, such as melanoma, lung cancer, and renal cell carcinoma, prostate cancer has generally failed to show a significant response. However, small series of prostate cancer patients have show

APA, Harvard, Vancouver, ISO, and other styles

2

Podrazil, Michal, Radek Špíšek, and Jiřina Bartůňková. "Immunotherapy for prostate cancer." Urologie pro praxi 17, no. 4 (2016): 159–66. http://dx.doi.org/10.36290/uro.2016.041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bronte, Vincenzo, Tihana Kasic, Giorgia Gri, et al. "Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers." Journal of Experimental Medicine 201, no. 8 (2005): 1257–68. http://dx.doi.org/10.1084/jem.20042028.

Full text

Abstract:

Immunotherapy may provide valid alternative therapy for patients with hormone-refractory metastatic prostate cancer. However, if the tumor environment exerts a suppressive action on antigen-specific tumor-infiltrating lymphocytes (TIL), immunotherapy will achieve little, if any, success. In this study, we analyzed the modulation of TIL responses by the tumor environment using collagen gel matrix–supported organ cultures of human prostate carcinomas. Our results indicate that human prostatic adenocarcinomas are infiltrated by terminally differentiated cytotoxic T lymphocytes that are, however,

APA, Harvard, Vancouver, ISO, and other styles

4

De Velasco, Marco A., and Hirotsugu Uemura. "Prostate cancer immunotherapy." Current Opinion in Urology 28, no. 1 (2018): 15–24. http://dx.doi.org/10.1097/mou.0000000000000462.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

McNeel, Douglas G. "Prostate cancer immunotherapy." Current Opinion in Urology 17, no. 3 (2007): 175–81. http://dx.doi.org/10.1097/mou.0b013e3280eb10eb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Madan, Ravi A., and James L. Gulley. "Prostate cancer immunotherapy." Current Opinion in Supportive and Palliative Care 11, no. 3 (2017): 225–30. http://dx.doi.org/10.1097/spc.0000000000000278.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bansal, Dhruv, Melissa A. Reimers, Eric M. Knoche, and Russell K. Pachynski. "Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer." Cancers 13, no. 2 (2021): 334. http://dx.doi.org/10.3390/cancers13020334.

Full text

Abstract:

Although most prostate cancers are localized, and the majority are curable, recurrences occur in approximately 35% of men. Among patients with prostate-specific antigen (PSA) recurrence and PSA doubling time (PSADT) less than 15 months after radical prostatectomy, prostate cancer accounted for approximately 90% of the deaths by 15 years after recurrence. An immunosuppressive tumor microenvironment (TME) and impaired cellular immunity are likely largely responsible for the limited utility of checkpoint inhibitors (CPIs) in advanced prostate cancer compared with other tumor types. Thus, for immu

APA, Harvard, Vancouver, ISO, and other styles

8

Bolat, Deniz, and Ayfer Haydaroğlu. "Immunotherapy in Prostate Cancer." Bulletin of Urooncology 18, no. 2 (2019): 67–72. http://dx.doi.org/10.4274/uob.galenos.2018.1142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

So-Rosillo, Rosendo, and Eric J. Small. "Immunotherapy for Prostate Cancer." American Journal of Cancer 5, no. 5 (2006): 331–39. http://dx.doi.org/10.2165/00024669-200605050-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Karan, Dev, and Peter Van Veldhuizen. "Editorial: Prostate Cancer Immunotherapy." Current Cancer Therapy Reviews 8, no. 4 (2012): 237. http://dx.doi.org/10.2174/157339412804143078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Karan, Dr Dev, and Peter Van Veldhuizen. "Editorial: Prostate Cancer Immunotherapy." Current Cancer Therapy Reviews 8, no. 4 (2012): 237. http://dx.doi.org/10.2174/1573394711208040237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Doehn, Christian. "Immunotherapy of Prostate Cancer." European Urology 53, no. 4 (2008): 681–83. http://dx.doi.org/10.1016/j.eururo.2007.12.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Kaminski, Joseph M., James B. Summers, Matthew B. Ward, Mark R. Huber, and Boris Minev. "Immunotherapy and prostate cancer." Cancer Treatment Reviews 29, no. 3 (2003): 199–209. http://dx.doi.org/10.1016/s0305-7372(03)00005-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Venturini, Nicholas J., and Charles G. Drake. "Immunotherapy for Prostate Cancer." Cold Spring Harbor Perspectives in Medicine 9, no. 5 (2018): a030627. http://dx.doi.org/10.1101/cshperspect.a030627.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Slovin, Susan F. "Immunotherapy for prostate cancer." Current Opinion in Urology 26, no. 6 (2016): 529–34. http://dx.doi.org/10.1097/mou.0000000000000334.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Drake, C. "Immunotherapy for Prostate Cancer?" Annals of Oncology 25 (September 2014): iv15. http://dx.doi.org/10.1093/annonc/mdu298.4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

FONG, L. "Immunotherapy for prostate cancer." Seminars in Oncology 30, no. 5 (2003): 649–58. http://dx.doi.org/10.1016/s0093-7754(03)00350-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

K., R., Christopher Whelan, and Eugene Kwon. "Immunotherapy for Prostate Cancer." Current Pharmaceutical Design 12, no. 7 (2006): 807–17. http://dx.doi.org/10.2174/138161206776056001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Fong, Lawrence, and Eric J. Small. "Immunotherapy for prostate cancer." Current Prostate Reports 5, no. 1 (2007): 5–12. http://dx.doi.org/10.1007/s11918-007-0001-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Rini, Brian I., and Eric J. Small. "Immunotherapy for prostate cancer." Current Oncology Reports 3, no. 5 (2001): 418–23. http://dx.doi.org/10.1007/s11912-001-0028-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Fong, Lawrence, and Eric J. Small. "Immunotherapy for prostate cancer." Current Oncology Reports 9, no. 3 (2007): 226–33. http://dx.doi.org/10.1007/s11912-007-0026-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Freedland, Stephen J., Allan J. Pantuck, Jeffrey Weider, Amnon Zisman, and Arie S. Belldegrun. "Immunotherapy of prostate cancer." Current Urology Reports 2, no. 3 (2001): 242–47. http://dx.doi.org/10.1007/s11934-001-0086-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Fong, Lawrence, and Eric J. Small. "Immunotherapy for prostate cancer." Current Urology Reports 7, no. 3 (2006): 239–46. http://dx.doi.org/10.1007/s11934-006-0027-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Tse, Brian Wan-Chi, Lidija Jovanovic, Colleen Coyne Nelson, Paul de Souza, Carl Andrew Power, and Pamela Joan Russell. "From Bench to Bedside: Immunotherapy for Prostate Cancer." BioMed Research International 2014 (2014): 1–11. http://dx.doi.org/10.1155/2014/981434.

Full text

Abstract:

The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, immunotherapy has also emerged as an option for the treatment of this disease following the approval of sipuleucel-T by the FDA in 2010. Immunotherapy is a rational approach for prostate cancer based on a body of evidence suggesting these cancers are inherently immunogenic and, most importantly, that

APA, Harvard, Vancouver, ISO, and other styles

25

Movassaghi, Miyad, Rainjade Chung, Christopher B. Anderson, Mark Stein, Yvonne Saenger, and Izak Faiena. "Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances." Cancers 13, no. 19 (2021): 4757. http://dx.doi.org/10.3390/cancers13194757.

Full text

Abstract:

The use of immunotherapy has become a critical treatment modality in many advanced cancers. However, immunotherapy in prostate cancer has not been met with similar success. Multiple interrelated mechanisms, such as low tumor mutational burden, immunosuppressive cells, and impaired cellular immunity, appear to subvert the immune system, creating an immunosuppressive tumor microenvironment and leading to lower treatment efficacy in advanced prostate cancer. The lethality of metastatic castrate-resistant prostate cancer is driven by the lack of therapeutic regimens capable of generating durable r

APA, Harvard, Vancouver, ISO, and other styles

26

Tuygun, Can, and Hasan Bakirtas. "Immunotherapy in Metastatic Prostate Cancer." Türk Üroloji Seminerleri/Turkish Urology Seminars 1, no. 7 (2010): 201–6. http://dx.doi.org/10.5152/tus.2010.28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Havranek, E. G., M. A. Whelan, R. Greenhalgh, A. G. Dalgleish, and H. Pandha. "Advances in prostate cancer immunotherapy." Surgical Oncology 11, no. 1-2 (2002): 35–45. http://dx.doi.org/10.1016/s0960-7404(02)00012-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Drake, Charles G. "Immunotherapy for metastatic prostate cancer." Urologic Oncology: Seminars and Original Investigations 26, no. 4 (2008): 438–44. http://dx.doi.org/10.1016/j.urolonc.2007.03.029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Laccetti, Andrew L., and Sumit K. Subudhi. "Immunotherapy for metastatic prostate cancer." Current Opinion in Urology 27, no. 6 (2017): 566–71. http://dx.doi.org/10.1097/mou.0000000000000433.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Kantoff, P. W. "Immunotherapy for Advanced Prostate Cancer." Annals of Oncology 23 (September 2012): ix38. http://dx.doi.org/10.1093/annonc/mds378.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Patel, Devin, Rana McKay, and J. Kellogg Parsons. "Immunotherapy for Localized Prostate Cancer." Urologic Clinics of North America 47, no. 4 (2020): 443–56. http://dx.doi.org/10.1016/j.ucl.2020.07.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Randhawa, Manreet, and Robert Jones. "Immunotherapy in Advanced Prostate Cancer." European Oncology & Haematology 16, no. 1 (2020): 44. http://dx.doi.org/10.17925/eoh.2020.16.1.44.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Dalgleish, AG, MJA Perry, JD Eaton, D. Hrouda, SM Todryk, and RS Kirby. "The immunotherapy of prostate cancer." Prostate Cancer and Prostatic Diseases 3, no. 4 (2000): 303–7. http://dx.doi.org/10.1038/sj.pcan.4500487.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Henegan, John C., and Guru Sonpavde. "Promising immunotherapy for prostate cancer." Expert Opinion on Biological Therapy 18, no. 2 (2017): 109–20. http://dx.doi.org/10.1080/14712598.2018.1406916.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Rescigno, Pasquale, and Johann S. de Bono. "Immunotherapy for lethal prostate cancer." Nature Reviews Urology 16, no. 2 (2018): 69–70. http://dx.doi.org/10.1038/s41585-018-0121-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Madan, Ravi A., James L. Gulley, and Philip W. Kantoff. "Demystifying Immunotherapy in Prostate Cancer." Cancer Journal 19, no. 1 (2013): 50–58. http://dx.doi.org/10.1097/ppo.0b013e31828160a9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

May, Kenneth F., James L. Gulley, Charles G. Drake, Glenn Dranoff, and Philip W. Kantoff. "Prostate Cancer Immunotherapy: Figure 1." Clinical Cancer Research 17, no. 16 (2011): 5233–38. http://dx.doi.org/10.1158/1078-0432.ccr-10-3402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Slovin, SusanF. "Immunotherapy in metastatic prostate cancer." Indian Journal of Urology 32, no. 4 (2016): 271. http://dx.doi.org/10.4103/0970-1591.191240.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Jähnisch, Hanka, Susanne Füssel, Andrea Kiessling, et al. "Dendritic Cell-Based Immunotherapy for Prostate Cancer." Clinical and Developmental Immunology 2010 (2010): 1–8. http://dx.doi.org/10.1155/2010/517493.

Full text

Abstract:

Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens. These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction of immunological and clinical responses in prostate cancer patients. In this conte

APA, Harvard, Vancouver, ISO, and other styles

40

Webster, W. Scott, Eric J. Small, Brian I. Rini, and Eugene D. Kwon. "Prostate Cancer Immunology: Biology, Therapeutics, and Challenges." Journal of Clinical Oncology 23, no. 32 (2005): 8262–69. http://dx.doi.org/10.1200/jco.2005.03.4595.

Full text

Abstract:

A number of recently developed and promising approaches to antitumoral immunotherapy are being investigated as potential treatments for advanced prostate cancer. These approaches largely revolve around strategies to increase antigen-specific T-cell activation against prostate tumors as well as precise manipulations of critical co-regulatory receptors that help to maintain and prolong the activity of antigen-presenting cells and T cells that are capable of mediating tumor regression. Herein, we describe the experience with the most recent and promising approaches pertaining to prostate cancer i

APA, Harvard, Vancouver, ISO, and other styles

41

Boikos, Sosipatros A., and Emmanuel S. Antonarakis. "Immunotherapy for Prostate Cancer Enters Its Golden Age." Clinical Medicine Insights: Oncology 6 (January 2012): CMO.S7475. http://dx.doi.org/10.4137/cmo.s7475.

Full text

Abstract:

In the United States, prostate cancer is the most frequent malignancy in men and ranks second in terms of mortality. Although recurrent or metastatic disease can be managed initially with androgen ablation, most patients eventually develop castration-resistant disease within a number of years, for which conventional treatments (eg, chemotherapy) provide only modest benefits. In the last few years, immunotherapy has emerged as an exciting therapeutic modality for advanced prostate cancer, and this field is evolving rapidly. Encouragingly, the US Food and Drug Administration (FDA) has recently a

APA, Harvard, Vancouver, ISO, and other styles

42

Kwon, J. T. W., R. J. Bryant, and E. E. Parkes. "The tumor microenvironment and immune responses in prostate cancer patients." Endocrine-Related Cancer 28, no. 8 (2021): T95—T107. http://dx.doi.org/10.1530/erc-21-0149.

Full text

Abstract:

The landscape of cancer treatment has been transformed over the past decade by the success of immune-targeting therapies. However, despite sipuleucel-T being the first-ever approved vaccine for cancer and the first immunotherapy licensed for prostate cancer in 2010, immunotherapy has since seen limited success in the treatment of prostate cancer. The tumour microenvironment of prostate cancer presents particular barriers for immunotherapy. Moreover, prostate cancer is distinguished by being one of only two solid tumours where increased T cell-infiltration correlates with a poorer, rather than

APA, Harvard, Vancouver, ISO, and other styles

43

Cha, Edward, and Lawrence Fong. "Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches." Journal of Clinical Oncology 29, no. 27 (2011): 3677–85. http://dx.doi.org/10.1200/jco.2010.34.5025.

Full text

Abstract:

Although prostate cancer was not historically considered to be a particularly immune-responsive cancer, recent clinical trials have demonstrated that immunotherapy for prostate cancer can lead to improvements in overall survival (OS). These studies include randomized controlled trials with sipuleucel-T and another with PROSTVAC-VF, both of which rely on stimulating the immune system to target prostate proteins. This review discusses the most promising developments over the past year in immune-based therapy for prostate cancer and the opportunities that lie ahead. Recent randomized immunotherap

APA, Harvard, Vancouver, ISO, and other styles

44

von Boehmer, L., P. Wild, L. Keller, et al. "Cancer testis antigen expression and immune responses by prostate cancer patients: Implications for prognosis and immunotherapy." Journal of Clinical Oncology 27, no. 15_suppl (2009): e16101-e16101. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e16101.

Full text

Abstract:

e16101 Background: Prostate cancer (PC) is the most frequent malignancy in men and it continues to be one of the most common fatal cancers. Treatment options in advanced castration-resistant prostate cancer (CRPC) are limited. Cancer testis (CT) antigens are expressed in a variety of human cancers, but not in normal tissues except for MHC deficient spermatogonia, and represent promising targets for immunotherapy. Little is known about CT antigen expression in relation to disease progression. The aim of this study was to investigate which CT antigens are expressed and immunogenic and hence repr

APA, Harvard, Vancouver, ISO, and other styles

45

Rini, Brian I., and Eric J. Small. "The potential for prostate cancer immunotherapy." Critical Reviews in Oncology/Hematology 46 (June 2003): 117–25. http://dx.doi.org/10.1016/s1040-8428(03)00069-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Kates, Max, and Charles G. Drake. "Immunotherapy for Prostate Cancer—Why Now?" Urology Practice 4, no. 4 (2017): 329–34. http://dx.doi.org/10.1016/j.urpr.2016.07.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Dubey, Seema, Peter VanVeldhuizen, and Dev Karan. "Adenovirus-based Immunotherapy for Prostate Cancer." Current Cancer Therapy Reviews 8, no. 4 (2012): 264–70. http://dx.doi.org/10.2174/157339412804143087.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Hashmi, Mehmood, Dev Karan, Sneha Phadke, Yogen Saunthararajah, Suman Kambhampati, and Peter Van Veldhuizen. "Prostate Cancer Immunotherapy: An Evolving Field." Current Cancer Therapy Reviews 8, no. 4 (2012): 274–82. http://dx.doi.org/10.2174/157339412804143159.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Dubey, Seema, Peter VanVeldhuizen, and Dev Karan. "Adenovirus-based Immunotherapy for Prostate Cancer." Current Cancer Therapy Reviews 8, no. 4 (2012): 264–70. http://dx.doi.org/10.2174/1573394711208040264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Hashmi, Mehmood, Dev Karan, Sneha Phadke, Yogen Saunthararajah, Suman Kambhampati, and Peter Van Veldhuizen. "Prostate Cancer Immunotherapy: An Evolving Field." Current Cancer Therapy Reviews 8, no. 4 (2012): 274–82. http://dx.doi.org/10.2174/1573394711208040274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!